Trial Profile
Post-marketing phase IV trial of Ad5FGF-4 (Generx)
Status:
Planning
Phase of Trial:
Phase IV
Latest Information Update: 08 Apr 2015
Price :
$35
*
At a glance
- Drugs Alferminogene-tadenovec (Primary)
- Indications Angina pectoris
- Focus Adverse reactions; Therapeutic Use
- 08 Apr 2015 New trial record